Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316) ; volume:30 ; number:6 ; day:24 ; month:7 ; year:2023 ; pages:943-951 ; date:11.2023
Breast cancer ; 30, Heft 6 (24.7.2023), 943-951, 11.2023
- Urheber
-
Futamura, Manabu
Nakayama, Takahiro
Yoshinami, Tetsuhiro
Oshiro, Chiya
Ishihara, Mikiya
Morita, Midori
Watanabe, Akira
Tanigichi, Azusa
Tsukabe, Masami
Shimoda, Masafumi
Nitta, Kanae
Chihara, Yoko
Yasojima, Hiroyuki
Ouchi, Yoshimi
Tokumaru, Yoshihisa
Masuda, Norikazu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12282-023-01485-y
- URN
-
urn:nbn:de:101:1-2024010810085016144073
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Futamura, Manabu
- Nakayama, Takahiro
- Yoshinami, Tetsuhiro
- Oshiro, Chiya
- Ishihara, Mikiya
- Morita, Midori
- Watanabe, Akira
- Tanigichi, Azusa
- Tsukabe, Masami
- Shimoda, Masafumi
- Nitta, Kanae
- Chihara, Yoko
- Yasojima, Hiroyuki
- Ouchi, Yoshimi
- Tokumaru, Yoshihisa
- Masuda, Norikazu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare